Connection

Elizabeth Garrett-Mayer to Bevacizumab

Back to Details
This is a "connection" page, showing publications Elizabeth Garrett-Mayer has written about Bevacizumab.
Elizabeth Garrett-Mayer
Connection Strength
0.024
Bevacizumab
  1. Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. Oncology. 2012; 82(2):67-74.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.